In vitro determination of tetanus toxicity by an endopeptidase assay linked to a ganglioside-binding step

Toxicology in Vitro

Volumn 24, Issue 3, 2010, Pages 988-994

  Behrensdorf Nicol, Heike A ^a   Bonifas, Ursula ^a   Kegel, Birgit ^a   Silberbach, Katja ^a   Krämer, Beate ^a   Weißer, Karin ^a  

^a PAUL EHRLICH INSTITUT   (Germany)

Author keywords

Binding assay; Clostridial neurotoxins; Endopeptidase assay; Gangliosides; In vitro; Synaptobrevin; Tetanus neurotoxin

Indexed keywords

GANGLIOSIDE; PROTEINASE; TETANUS TOXIN;

ARTICLE; BINDING ASSAY; CONTROLLED STUDY; ENZYME ASSAY; ENZYME BINDING; IN VITRO STUDY; RELIABILITY; TOXICITY TESTING; TOXIN ANALYSIS;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOPEPTIDASES; GANGLIOSIDES; INDICATORS AND REAGENTS; MICE; R-SNARE PROTEINS; TETANUS TOXIN; TETANUS TOXOID;

ANIMALIA; CAVIA; MUS;

EID: 77649189600     PISSN: 08872333     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tiv.2009.12.018     Document Type: Article

References (40)

1. Behrensdorf-Nicol H.A., Kegel B., Bonifas U., Silberbach K., Klimek J., Weißer K., and Krämer B. Residual enzymatic activity of the tetanus toxin light chain present in tetanus toxoid batches used for vaccine production. Vaccine 26 (2008) 3835-3841
2. Bolgiano B., Fowler S., Turner K., Sesardic D., Xing D.K., Crane D.T., and Corbel M.J. Monitoring of diphtheria, pertussis and tetanus toxoids by circular dichroism, fluorescence spectroscopy and size-exclusion chromatography. Dev. Biol. 103 (2000) 51-59
3. Chen C., Baldwin M.R., and Barbieri J.T. Molecular basis for tetanus toxin co-receptor interactions. Biochemistry 47 (2008) 7179-7186
4. Chen C., Fu Z., Kim J.J., Barbieri J.T., and Baldwin M.R. Gangliosides as high affinity receptors for tetanus neurotoxin. J. Biol. Chem. 284 (2009) 26569-26577
5. Christian T., and Shine N. Capture assay for botulinum neurotoxin type A utilizing the receptor protein SV2c. Toxicon 51 Suppl. 1 (2008) 2
6. Corbel M.J., and Xing D.K. Toxicity and potency evaluation of pertussis vaccines. Exp. Rev. Vac. 3 (2004) 89-101
7. Council of Europe, 2008a. Tetanus Vaccine (adsorbed), Monograph 0452, sixth ed. In: European Pharmacopoeia.
8. Council of Europe, 2008b. Tetanus Vaccine for Veterinary Use, Monograph 0697, sixth ed. In: European Pharmacopoeia.
9. Dekant W., Vamvakas S., and Henschler D. Wichtige Gifte und Vergiftungen. In: Forth W., Henschler D., Rummel W., Förstermann U., and Starke K. (Eds). Allgemeine und spezielle Pharmakologie und Toxikologie. 8th edition (2001), Urban & Fischer Verlag, München 985-1149
10. Dong M., Richards D.A., Goodnough M.C., Tepp W.H., Johnson E.A., and Chapman E.R. Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. J. Cell Biol. 162 (2003) 1293-1303
11. Dong M., Yeh F., Tepp W.H., Dean C., Johnson E.A., Janz R., and Chapman E.R. SV2 is the protein receptor for botulinum neurotoxin A. Science 312 (2006) 592-596
12. Ekong T.A., Feavers I.M., and Sesardic D. Recombinant SNAP-25 is an effective substrate for Clostridium botulinum type A toxin endopeptidase activity in vitro. Microbiology 143 (1997) 3337-3347
13. Evans E.R., Skipper P.J., and Shone C.C. An assay for botulinum toxin types A, B and F that requires both functional binding and catalytic activities within the neurotoxin. J. Appl. Microbiol. 107 (2009) 1384-1391
14. Fotinou C., Emsley P., Black I., Ando H., Ishida H., Kiso M., Sinha K.A., Fairweather N.F., and Isaacs N.W. The crystal structure of tetanus toxin HC fragment complexed with a synthetic GT1b analogue suggests cross-linking between ganglioside receptors and the toxin. J. Biol. Chem. 276 (2001) 32274-32281
15. Gill D.M. Bacterial toxins: a table of lethal amounts. Microbiol. Rev. 46 (1982) 86-94
16. Gomez S.R., Xing D.K., Corbel M.J., Coote J., Parton R., and Yuen C.T. Development of a carbohydrate binding assay for the B-oligomer of pertussis toxin and toxoid. Anal. Biochem. 356 (2006) 244-253
17. Gomez S.R., Yuen C.T., Asokanathan C., Douglas-Bardsley A., Corbel M.J., Coote J.G., Parton R., and Xing D.K. ADP-ribosylation activity in pertussis vaccines and its relationship to the in vivo histamine-sensitisation test. Vaccine 25 (2007) 3311-3318
18. Habermann E., and Tayot J.L. Interaction of solid-phase gangliosides with tetanus toxin and toxoid. Toxicon 23 (1985) 913-920
19. Hallis B., James B.A., and Shone C.C. Development of novel assays for botulinum type A and B neurotoxins based on their endopeptidase activities. J. Clin. Microbiol. 34 (1996) 1934-1938
20. Hendriksen C., Arciniega J.L., Bruckner L., Chevalier M., Coppens E., Descamps J., Duchene M., Dusek D.M., Halder M., Kreeftenberg H., Maes A., Redhead K., Ravetkar S.D., Spieser J.M., and Swam H. The consistency approach for the quality control of vaccines. Biologicals 36 (2008) 73-77
21. Herreros J., Lalli G., Montecucco C., and Schiavo G. Tetanus toxin fragment C binds to a protein present in neuronal cell lines and motoneurons. J. Neurochem. 74 (2000) 1941-1950
22. Herreros J., Ng T., and Schiavo G. Lipid rafts act as specialized domains for tetanus toxin binding and internalization into neurons. Mol. Biol. Cell 12 (2001) 2947-2960
23. ICCVAM, 1997. Validation and Regulatory Acceptance of Toxicological Test Methods. NIH Publication No. 97-3981.
24. ICCVAM-NICEATM, 2008. Report on the ICCVAM-NICEATM/ECVAM Scientific Workshop on Alternative Methods to Refine, Reduce or Replace the Mouse LD50 Assay for Botulinum Toxin Testing. NIH Publication No. 08-6416.
25. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Validation of analytical procedures: Text and methodology. Harmonized tripartite guideline Q2(R1), 2005.
26. Jones R.G., Ochiai M., Liu Y., Ekong T., and Sesardic D. Development of improved SNAP25 endopeptidase immuno-assays for botulinum type A and E toxins. J. Immunol. Methods 329 (2008) 92-101
27. Kegel B., Bonifas U., Silberbach K., Krämer B., and Weißer K. In vitro determination of specific toxicity in tetanus vaccines. Dev. Biol. 111 (2002) 27-33
28. Kegel B., Behrensdorf-Nicol H.A., Bonifas U., Silberbach K., Klimek J., Krämer B., and Weißer K. An in vitro assay for detection of tetanus neurotoxin activity: using antibodies for recognizing the proteolytically generated cleavage product. Toxicol. in Vitro 21 (2007) 1641-1649
29. Leung T., Corran P.H., Gee C., Ekong T.A., and Sesardic D. Application of an in vitro endopeptidase assay for detection of residual toxin activity in tetanus toxoids. Dev. Biol. 111 (2002) 327-332
30. Munro P., Kojima H., Dupont J.L., Bossu J.L., Poulain B., and Boquet P. High sensitivity of mouse neuronal cells to tetanus toxin requires a GPI-anchored protein. Biochem. Biophys. Res. Commun. 289 (2001) 623-629
31. Pellizzari R., Rossetto O., Washbourne P., Tonello F., Nicotera P.L., and Montecucco C. In vitro biological activity and toxicity of tetanus and botulinum neurotoxins. Toxicol. Lett. 102-103 (1998) 191-197
32. Perpetuo E.A., Juliano L., Prado S.M., Fratelli F., Fernandes I., and Lebrun I. Development of an operational synaptobrevin-based fluorescent substrate for tetanus neurotoxin quantification. Biotechnol. Appl. Biochem. 36 (2002) 155-161
33. Qazi O., Sesardic D., Tierney R., Söderbäck Z., Crane D., Bolgiano B., and Fairweather N. Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines. Infect. Immunity 74 (2006) 4884-4891
34. Robinson J.P. Purification of tetanus toxin and its major peptides. Methods Enzymol. 165 (1988) 85-90
35. Rogers T.B., and Snyder S.H. High affinity binding of tetanus toxin to mammalian brain membranes. J. Biol. Chem. 256 (1981) 2402-2407
36. Russell W.M.S., and Burch R.L. The Principles of Humane Experimental Technique (1959), Methuen, London
37. Sesardic D., Corran P.H., Gee C., and Ekong T.A. In vitro approaches for estimating activity of tetanus toxin as an alternative assay for specific toxicity. In: Balls M., van Zeller A.M., and Halder M.E. (Eds). Progress in the Reduction, Refinement and Replacement of Animal Experimentation (2000), Elsevier, Amsterdam 969-974
38. Sesardic D. Potency and safety testing for toxins and anti-toxins - an overview. In: Proceedings of the International Symposium "Alternatives to animal testing: new approaches in the development and control of biologicals" (2008), EDQM, Strasbourg pp. 79-82
39. Straughan D.W. Progress in applying the three Rs to the potency testing of botulinum toxin type A. Altern. Lab. Anim. 34 (2006) 305-313
40. Worth A.P., and Balls M. The principles of validation and the ECVAM validation process. Altern. Lab. Anim. 30 Suppl. 2 (2002) 15-21